罗格列酮联合利拉鲁肽治疗青年2型糖尿病合并非酒精性脂肪肝患者的效果

Effect of Rosiglitazone Combined with Liraglutide in the Treatment of Young Patients with Type 2 Diabetes Complicated with Nonalcoholic Fatty Liver

目的:探讨罗格列酮联合利拉鲁肽治疗青年2型糖尿病合并非酒精性脂肪肝患者的效果。方法:选择2023年1—12月深圳市龙华区人民医院收治的60例青年2型糖尿病合并非酒精性脂肪肝患者作为研究对象,以随机数表法分为两组,各30例。对照组应用罗格列酮治疗,研究组应用罗格列酮联合利拉鲁肽治疗。比较两组临床疗效、血糖、糖化血红蛋白、甘油三酯、体重指数、肝功能及不良反应发生率。结果:研究组临床总有效率为93.33%,高于对照组的70.00%,差异有统计学意义(P<0.05)。治疗后,两组血糖、糖化血红蛋白、甘油三酯、体重指数均低于治疗前,且研究组均低于对照组,差异有统计学意义(P<0.05)。治疗后,两组γ-谷氨酰转移酶(GGT)、谷丙转氨酶(ALT)、谷草转氨酶(AST)水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率为10.00%,低于对照组的6.67%,但两组比较差异无统计学意义(P>0.05)。结论:罗格列酮联合利拉鲁肽治疗青年2型糖尿病合并非酒精性脂肪肝患者可降低血糖、血脂、体重指数,改善肝功能,且未明显增加不良反应。

Objective:To investigate the effect of Rosiglitazone combined with Liraglutide in the treatment of young patients with type 2 diabetes complicated with nonalcoholic fatty liver.Method:A total of 60 young patients with type 2 diabetes complicated with nonalcoholic fatty liver who treated in Longhua District People's Hospital of Shenzhen City from January to December 2023 were selected as the study objects,and they were divided into two groups by random number table method,with 30 cases in each group.The control group was treated with Rosiglitazone,and the study group was treated with Rosiglitazone combined with Liraglutide.The clinical efficacy,blood glucose,glycosylated hemoglobin,triglyceride,body mass index,liver function and incidence of adverse reactions were compared between two groups.Result:The total clinical effective rate of the study group was 93.33%,which was higher than 70.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of blood glucose,glycosylated hemoglobin,triglyceride,body mass index in two groups were lower than those before treatment,and those in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,γ-glutamyl transferase(GGT),alanine transaminase(ALT),aspartate transaminase(AST)levels in two groups were lower than those before treatment,and those in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 10.00%,which was lower than 6.67%in the control group,but there was no statistical significance between two groups(P>0.05).Conclusion:Rosiglitazone combined with Liraglutide in the treatment of young patients with type 2 diabetes complicated with nonalcoholic fatty liver can reduce blood glucose,blood lipid,body mass index,improve liver function,and do not significantly increase adverse reactions.